RAPT Therapeutics, Inc.
RAPT
$0.906
-$0.0151-1.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.01M | 6.45M | 6.69M | 7.74M | 6.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.47M | 19.79M | 29.33M | 32.52M | 33.22M |
| Operating Income | -54.47M | -19.79M | -29.33M | -32.52M | -33.22M |
| Income Before Tax | -53.25M | -18.43M | -27.66M | -30.52M | -30.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.25M | -18.43M | -27.66M | -30.52M | -30.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.25M | -18.43M | -27.66M | -30.52M | -30.88M |
| EBIT | -54.47M | -19.79M | -29.33M | -32.52M | -33.22M |
| EBITDA | -54.18M | -19.49M | -29.03M | -32.20M | -32.89M |
| EPS Basic | -1.14 | -0.47 | -0.71 | -0.79 | -0.80 |
| Normalized Basic EPS | -0.72 | -0.30 | -0.44 | -0.51 | -0.52 |
| EPS Diluted | -1.14 | -0.47 | -0.71 | -0.79 | -0.80 |
| Normalized Diluted EPS | -0.72 | -0.30 | -0.44 | -0.51 | -0.52 |
| Average Basic Shares Outstanding | 46.69M | 38.90M | 38.87M | 38.63M | 38.38M |
| Average Diluted Shares Outstanding | 46.69M | 38.90M | 38.87M | 38.63M | 38.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |